top of page
Search

January 2024 // Press Release

  • Sarah Farcy
  • Jan 18, 2024
  • 1 min read

Updated: 1 day ago

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510.


Synendos transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders.


ree
ree
ree



 
 

Recent Posts

See All
July 2025 // Press Release

Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy

 
 
July 2023 // Press Release

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking new findings on an endocannabinoid transporter at the 10th Gord

 
 
bottom of page